PTPI — Petros Pharmaceuticals Income Statement
0.000.00%
Annual income statement for Petros Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | R2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 7.81 | 5.99 | 5.82 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 6.21 | 3.7 | 4.19 | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 25.9 | 25.9 | 19.4 | 4.63 | 4.64 |
| Operating Profit | -18 | -19.9 | -13.6 | -4.63 | -4.64 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -8.99 | -20 | -8.16 | -0.705 | -4.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -8.99 | -20 | -8.16 | -0.705 | -4.5 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -8.99 | -20 | -8.16 | -14.3 | 1.91 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -8.99 | -20 | -13.8 | -26.8 | -43.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -206 | -193 | -159 | -41.1 | -1.79 |